Browse Category

EPA:ALDEI.PA News 20 January 2026

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 20.01.2026

Indian stocks opened lower Wednesday; Nifty fell 0.36% and Sensex dropped 0.47% amid global bond market volatility and rising yields. Deinove SA surged in pre-market trading on EURONEXT, with volume more than doubling its average. Software stocks slumped as AI disruption hit sector leaders, with major names posting steep losses. Persol Holdings shares rose 7.4% on stable fundamentals.

20 January 2026

EPA:ALDEI.PA·Stock Market

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026

MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.

GOOG stock price: Alphabet’s $185 billion AI spend plan keeps Google shares on edge into Monday

7 February 2026

Alphabet Class C shares (GOOG) fell 2.48% to $323.10 Friday after the company projected 2026 capital spending of up to $185 billion, more than double 2025 levels. CEO Sundar Pichai sold 32,500 shares earlier in the week under a pre-set plan. The Dow closed above 50,000 for the first time. Over 33.9 million GOOG shares traded, above recent volume.

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026

Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026

Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.

Go toTop